hepat
c
viru
hcv
hepatotrop
pathogen
signific
import
public
health
estim
million
peopl
worldwid
chronic
infect
risk
progress
cirrhosi
hepatocellular
carcinoma
endstag
liver
diseas
sequela
make
hcv
infect
common
caus
liver
transplant
brown
hcv
vaccin
avail
current
combin
pegyl
interferon
ifn
often
ineffect
poorli
toler
zeuzem
et
al
develop
addit
prevent
therapeut
altern
sever
hamper
lack
suitabl
anim
model
deficit
result
limit
speci
tropism
hcv
chimpanze
avail
immunocompet
vivo
experiment
system
use
limit
ethic
concern
restrict
avail
prohibit
high
cost
bukh
amen
smallanim
model
exogen
introduc
hcv
suscept
trait
could
significantli
acceler
preclin
test
vaccin
drug
candid
well
facilit
vivo
studi
hcv
pathogenesi
two
altern
necessarili
mutual
exclus
approach
propos
achiev
viru
could
adapt
infect
nonhuman
cell
rodent
tissu
could
human
fig
latter
might
achiev
either
xenotransplant
human
tissu
genet
manipul
express
ablat
key
gene
discuss
progress
prospect
toward
develop
smallanim
model
hcv
pathogenesi
particular
emphasi
creation
inbr
mous
model
hcv
envelop
viru
positivestrand
rna
genom
first
discov
caus
agent
nona
nonb
hepat
choo
et
al
sinc
becom
amen
cell
cultur
studi
rna
subgenom
hcv
pseudoparticl
hcvpp
recent
becom
possibl
studi
entir
viral
life
cycl
hcv
cell
cultur
system
hcvcc
bartenschlag
sparacio
tellinghuisen
et
al
hcv
use
sever
host
protein
enter
target
cell
human
hepatocyt
fig
minim
set
cellspecif
uptak
factor
includ
pileri
et
al
scarselli
et
al
tight
junction
molecul
evan
et
al
ocln
liu
et
al
ploss
et
al
intern
virion
receptormedi
endocytosi
follow
initi
genom
translat
intern
ribosom
entri
site
viru
encod
one
long
open
read
frame
gener
polyprotein
process
ten
individu
gene
product
hostencod
virallyencod
proteas
moradpour
et
al
addit
hcv
genom
function
templat
rnadepend
rna
replic
highli
errorpron
process
final
step
hcv
life
cycl
least
understood
recent
becom
amen
systemat
studi
structur
compon
core
protein
c
envelop
glycoprotein
grow
number
nonstructur
protein
includ
implic
product
infecti
virion
murray
et
al
infecti
particl
thought
form
bud
lumen
endoplasm
reticulum
follow
egress
cellular
secretori
pathway
mani
host
factor
might
requir
process
protein
involv
lipid
metabol
emerg
crucial
player
kapadia
chisari
miyanari
et
al
ye
inocul
sera
hcvinfect
individu
tissueculturederiv
viru
highli
immunodefici
result
detect
infect
ap
cmr
unpublish
data
resist
phenotyp
probabl
multifactori
least
partli
attribut
block
hcv
entri
although
mous
mediat
effici
hcvpp
uptak
ocln
must
human
origin
render
mous
cell
permiss
hcv
infect
ploss
et
al
express
mous
human
hepatoma
cell
lack
endogen
express
human
support
hcv
entri
howev
level
infect
substanti
lower
cell
express
primat
human
orthologu
probabl
due
reduc
affin
hcv
glycoprotein
mous
flint
et
al
although
mous
ident
human
protein
four
posit
crucial
interact
hcv
asn
phe
asp
higginbottom
et
al
conserv
murin
sequenc
hcv
howev
adapt
vitro
use
mous
bitzegeio
pietschmann
intern
symposium
hepat
c
viru
relat
virus
abstract
hcv
glycoprotein
remark
plastic
shown
continu
escap
viru
neutral
antibodi
cours
chronic
infect
von
hahn
et
al
flexibl
allow
select
three
mutat
serial
passag
hcv
human
cell
express
mous
togeth
chang
enhanc
mous
uptak
level
compar
infect
use
human
orthologu
similar
approach
could
envis
adapt
hcv
entri
mous
ocln
although
might
straightforward
unlik
welldocu
bind
pileri
et
al
clear
whether
hcv
interact
physic
ocln
addit
adapt
mutat
requir
use
mous
might
compat
chang
need
allow
engag
mous
ocln
uncertain
whether
murinetrop
hcv
would
infect
mous
hepatocyt
effici
human
cell
express
mous
entri
factor
select
mous
cell
might
lack
necessari
intracellular
factor
howev
murin
hcv
glycoprotein
could
principl
produc
viru
effici
enter
mous
cell
therebi
overcom
first
block
viral
life
cycl
fig
hydrodynam
transfect
hcv
genom
rna
cytoplasm
mous
hepatocyt
fail
initi
viral
replic
indic
addit
postentri
restrict
might
exist
mccaffrey
et
al
realtim
imag
firefli
luciferas
express
live
mice
shown
hcv
intern
ribosom
entri
site
function
mous
liver
cell
indic
restrict
occur
initi
translat
mccaffrey
et
al
hcv
genom
express
antibioticselect
marker
neomycin
phosphotransferas
replic
mous
hepat
cell
line
uprichard
et
al
zhu
et
al
select
similar
hcv
antibioticresist
replicon
human
cell
line
result
appear
adapt
mutat
often
significantli
increas
replic
effici
reengin
parent
genom
bartenschlag
sparacio
moradpour
et
al
although
mutat
also
occur
replic
antibioticresist
hcv
replicon
mous
cell
seem
random
rather
adapt
uprichard
et
al
none
significantli
enhanc
replic
effici
mous
cell
environ
reintroduc
parent
subgenom
zhu
et
al
suggest
although
essenti
cellular
factor
support
hcv
replic
probabl
present
mous
cell
viral
encod
replic
machineri
might
mesh
effici
murin
counterpart
drug
select
proven
strategi
establish
hcv
rna
replic
cell
natur
less
permiss
nonhepat
human
mous
cell
howev
approach
translat
easili
live
anim
due
broad
toxic
possibl
solut
could
express
cdna
transgen
encod
entir
hcv
genom
case
hbv
transgen
mice
replic
secret
hbv
crucial
studi
hbv
immunobiolog
pathogenesi
chisari
et
al
product
infecti
hcv
stabli
hcv
cdnatransfect
report
cai
et
al
case
gener
proper
end
hcv
rna
genom
crucial
ensur
effici
replic
initi
although
approach
appeal
simpli
produc
greater
abund
replicationcompet
hcv
rna
might
suffici
initi
sustain
replic
mous
liver
creat
system
vivo
select
hcv
genom
express
heterolog
select
marker
fah
could
use
complement
hepatotox
fah
defici
engin
mice
gromp
et
al
therebi
take
advantag
select
pressur
would
appli
vivo
hcv
replic
mous
hepatocyt
highlight
previou
studi
shown
hcv
entri
replic
occur
appropri
murin
environ
whether
hcv
virion
assembl
releas
mous
cell
remain
unknown
mous
hepatoma
cell
harbour
fulllength
hcv
genom
found
releas
infecti
viru
uprichard
et
al
howev
lack
virion
product
might
due
low
level
rna
accumul
possibl
increas
viral
replic
also
allow
detect
infecti
viru
addit
adapt
step
might
necessari
select
genom
assembl
compet
mous
cell
environ
ideal
viral
adapt
would
culmin
genom
recapitul
viral
life
cycl
mous
cell
would
repres
signific
step
toward
readili
avail
smallanim
model
hcv
fig
consid
howev
modif
affect
speci
tropism
might
also
signific
effect
immun
respons
pathogenesi
clear
clinic
featur
observ
human
would
recapitul
model
nonetheless
easili
access
costeffect
model
would
use
investig
least
aspect
viral
growth
vivo
adapt
murin
environ
support
replic
wildtyp
hcv
altern
approach
alreadi
met
success
chimer
mice
harbour
hcvpermiss
tissu
obtain
transplant
human
hepatocyt
mous
recipi
liver
injuri
sever
immunodefici
fig
meuleman
lerouxroel
commonli
use
recipi
strain
urokinasetyp
plasminogen
activ
upa
transgen
mous
transgen
express
liver
driven
albumin
alb
promot
albupa
transgen
overexpress
hepatotox
result
homozyg
mice
sever
liver
damag
heckel
et
al
rescu
transplant
nontransgen
human
hepatocyt
chimericliv
mice
suscept
human
hepatotrop
pathogen
includ
hbv
hcv
well
malaria
parasit
dandri
et
al
mercer
et
al
morosan
et
al
inocul
hcvcc
sera
hcvposit
patient
mice
lead
rapid
increas
viraemia
sustain
sever
week
lindenbach
et
al
mercer
et
al
meuleman
et
al
xenotranspl
human
mice
hold
great
potenti
mean
assess
drug
vaccin
efficaci
meuleman
lerouxroel
exampl
use
show
vivo
hcv
infect
prevent
antibodi
direct
meuleman
et
al
well
polyclon
antibodi
obtain
chronic
infect
patient
vanwolleghem
et
al
chimer
mice
also
use
studi
pharmacokinet
drug
toxic
katoh
et
al
fact
accur
reproduc
toxicolog
featur
hcv
proteas
inhibitor
biln
vanwolleghem
et
al
compound
withdrawn
clinic
develop
occurr
cardiotox
side
effect
primat
unfortun
chimericliv
mice
produc
small
number
use
limit
logist
constraint
substanti
variabl
might
possibl
overcom
issu
use
altern
liver
injuri
model
anim
target
fah
disrupt
alreadi
success
engraft
human
hepatocyt
azuma
et
al
bissig
et
al
yet
shown
suscept
hcv
hbv
pathogenesi
immun
studi
also
limit
liver
chimer
mice
anim
lack
function
immun
requir
avoid
reject
xenograft
overcom
problem
substanti
effort
way
combin
human
liver
model
mice
harbour
human
haematolymphoid
system
fig
legrand
et
al
mice
gener
engraft
suspens
human
haematopoiet
progenitor
stem
cell
immunodefici
anim
success
human
immun
reconstitut
anim
elicit
virusspecif
immun
respons
legrand
et
al
strowig
et
al
merg
hepat
haematolymphoid
reconstitut
singl
recipi
allow
studi
pathogenesi
immun
correl
mechan
persist
hcv
human
hepatotrop
pathogen
fig
xenograft
model
provid
uniqu
opportun
studi
hcv
biolog
human
hepatocyt
monitor
human
immun
respons
vivo
howev
gener
type
human
mice
requir
substanti
infrastructur
advanc
technic
skill
scarciti
adequ
human
primari
materi
remain
signific
logist
challeng
therefor
crucial
improv
distribut
avail
materi
develop
reproduc
robust
protocol
vitro
expans
differenti
hepatocyt
haematopoiet
progenitor
stem
cell
renew
sourc
embryon
induc
pluripot
stem
cell
inbr
mous
model
inherit
suscept
hcv
would
overcom
technic
difficulti
xenotransplant
model
challeng
systemat
identifi
overcom
restrict
hcv
growth
mous
cell
level
pathogen
entri
preced
success
genet
human
receptor
andor
coreceptor
mous
cell
human
pathogen
polioviru
racaniello
ren
measl
viru
sellin
horvat
human
coronaviru
lassnig
et
al
human
immunodefici
viru
klotman
notkin
listeria
monocytogen
lecuit
et
al
discoveri
essenti
hcv
entri
factor
pileri
et
al
transgen
mice
express
human
protein
wide
varieti
tissu
produc
masciopinto
et
al
howev
although
bind
recombin
liver
thymocyt
splenic
lymphocyt
increas
comparison
nontransgen
control
human
mice
resist
hcv
infect
led
conclus
express
human
alon
insuffici
confer
suscept
hcv
infect
mice
enthusiasm
creat
inbr
mous
model
hcv
recent
rekindl
identif
ocln
second
human
factor
essenti
overcom
crossspeci
barrier
level
entri
ploss
et
al
howev
accur
reproduc
complex
process
hcv
entri
vivo
import
achiev
nativ
express
pattern
human
hcv
entri
factor
orthologu
advanc
mous
genet
includ
bacteri
artifici
chromosom
transgen
knockin
approach
undoubtedli
crucial
achiev
model
would
allow
hcvglycoproteinmedi
entri
inbr
mous
strain
would
invalu
tool
analys
hcv
entri
vivo
preclin
test
new
intervent
strategi
fig
although
minim
human
factor
crucial
viral
uptak
defin
essenti
host
factor
requir
replic
less
clear
human
sipl
report
increas
hcv
replic
otherwis
nonpermiss
cell
line
yeh
et
al
subsequ
shown
slightli
enhanc
replic
mous
hepatoma
cell
line
express
human
yeh
et
al
howev
list
cellular
compon
implic
hcv
replic
still
grow
tabl
ng
et
al
randal
et
al
supekova
et
al
tai
et
al
vaillancourt
et
al
wang
et
al
watashi
et
al
unfortun
independ
studi
often
minim
overlap
relev
mani
interact
hcv
biolog
remain
demonstr
although
aminoacid
sequenc
protein
conserv
mice
human
possibl
diverg
crucial
function
domain
reduc
capac
certain
murin
factor
support
hcv
replic
comprehens
gainoffunct
analysi
individu
human
gene
mous
cell
yet
complet
altern
function
cdna
complement
screen
could
less
bias
approach
identifi
specif
human
factor
requir
effici
hcv
rna
replic
mous
cell
howev
screen
would
particularli
challeng
one
gene
requir
establish
effici
replic
cellular
mirna
also
profoundli
influenc
viru
replic
pathogenesi
gottwein
cullen
two
liverspecif
shown
affect
hcv
rna
translat
replic
jopl
et
al
murakami
et
al
mous
ident
sequenc
show
similar
express
level
human
counterpart
chang
et
al
howev
slight
sequenc
diverg
differenti
abund
mirna
seed
site
hcv
genom
might
affect
tropism
pedersen
et
al
addit
miss
incompat
posit
regul
hcv
replic
dominantneg
restrict
factor
might
present
mous
cell
alter
exacerb
innat
antivir
respons
inabl
hcv
protein
overcom
murin
defenc
mousespecif
restrict
factor
similar
control
retrovir
cytidin
impair
hcv
replic
mous
cell
variat
type
intens
antivir
respons
host
known
restrict
tropism
certain
virus
myxoma
viru
permiss
mous
cell
impair
ifn
respons
werden
et
al
induct
type
ifn
also
extrem
import
cellular
defenc
hcv
counteract
cleavag
sever
host
protein
viral
serin
proteas
keller
et
al
agreement
subgenom
hcv
rna
shown
replic
effici
pkrdefici
mous
embryon
fibroblast
wildtyp
cell
chang
et
al
summari
due
limit
capac
mous
cell
support
hcv
life
cycl
sever
genet
adapt
human
murin
host
requir
creat
inbr
mous
model
hcv
infect
addit
combin
human
mous
strain
harbour
target
downregul
key
molecul
involv
antivir
signal
could
creat
environ
suitabl
initi
sustain
viral
replic
fig
although
genet
disrupt
molecul
critic
mediat
antivir
respons
probabl
alter
immun
pathogenesi
inbr
mous
model
sustain
hcv
infect
could
platform
improv
design
mimic
close
clinic
featur
human
hepat
hepat
c
complex
medic
problem
aggrav
insuffici
efficaci
global
access
current
standardofcar
medic
lack
vaccin
achiev
widespread
protect
robust
anim
model
easili
propag
recapitul
part
viral
life
cycl
would
instrument
improv
understand
hcv
pathogenesi
would
also
help
guid
drug
vaccin
develop
sidebar
furthermor
abil
model
liver
diseas
progress
crucial
devis
new
intervent
strategi
abl
slow
even
revers
liver
cirrhosi
fibrosi
probabl
deciph
barrier
hcv
replic
mous
cell
provid
rich
insight
interact
creat
blueprint
robust
mous
model
hcv
infect
